Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Bayer Seeks To Buy Monsanto in $66 Billion Deal

XTALKS VITALS NEWS

Best known for the discovery of aspirin, Bayer’s acquisition of Monsanto would make it the world’s largest seed and crop spray supplier.

Tweetables from this article:

Tweet: Monsanto and Bayer will need to secure the approval of regulators in the US, Canada, the EU and Brazil http://ctt.ec/ODRnv+Monsanto and Bayer will need to secure the approval of regulators in the US, Canada, the EU and Brazil.

Share this!

September 21, 2016 | by Sarah Hand, M.Sc.

German pharmaceutical company Bayer has announced its intention to acquire the US-based agribusiness company Monsanto in a $66 billion deal. Best known for the discovery of aspirin, Bayer’s acquisition of Monsanto would make it the world’s largest seed and crop spray supplier.

After four months of negotiations, the companies have agreed upon an all-cash deal valuing Monsanto’s shares at $128 apiece. Hugh Grant, CEO of Monsanto will reportedly earn over $135 million if the sale goes through.

“Today’s announcement is a testament to everything we’ve achieved and the value that we have created for our stakeholders at Monsanto,” said Grant. “We believe that this combination with Bayer represents the most compelling value for our shareowners, with the most certainty through the all-cash consideration.”

Despite mutual agreement between the two companies, the merger will now face the scrutiny of US regulators. Following last year’s merger between Dow Chemical and DuPont, and this year’s deal between ChemChina and Syngenta, the number of global companies in agribusiness is quickly shrinking.



Industry experts are pointing to bumper harvests and declining crop prices as a main driver of consolidation in the agricultural industry. According to farmer’s groups, this reduction in the number of different companies investing in new agricultural technologies could drive up the cost of proprietary seeds and chemical sprays.

If they’re successful, the Bayer-Monsanto merger will be the largest cash only deal on record, as well as the biggest acquisition of an American company by an overseas business. To complete the deal, Bayer will need to secure the approval of regulators in the US, Canada, the EU and Brazil.

“We are entering a new era in agriculture – one with significant challenges that demand new, sustainable solutions and technologies to enable growers to produce more with less,” said Grant. “This combination with Bayer will deliver just that – an innovation engine that pairs Bayer’s crop protection portfolio with our world-class seeds and traits and digital agriculture tools to help growers overcome the obstacles of tomorrow. Together Monsanto and Bayer will build on our proud tradition and respective track records of innovation in the agriculture industry, delivering a more comprehensive and broader set of solutions to growers.”


Keywords: Merger, Agribusiness, Aspirin


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.